Vontobel Holding Ltd. Cuts Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Vontobel Holding Ltd. lowered its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 61.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,300 shares of the biopharmaceutical company’s stock after selling 93,800 shares during the quarter. Vontobel Holding Ltd.’s holdings in Sangamo Therapeutics were worth $38,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in shares of Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Sangamo Therapeutics by 2,319.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 25,000 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Sangamo Therapeutics during the 4th quarter valued at approximately $28,000. Captrust Financial Advisors purchased a new position in shares of Sangamo Therapeutics during the 4th quarter valued at approximately $30,000. Finally, LPL Financial LLC lifted its position in shares of Sangamo Therapeutics by 113.5% during the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 16,498 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Analyst Ratings Changes

SGMO has been the topic of several recent research reports. Wall Street Zen cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 30th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, June 24th. Barclays reduced their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Sangamo Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.50.

Sangamo Therapeutics Stock Performance

Shares of Sangamo Therapeutics stock opened at $0.53 on Thursday. Sangamo Therapeutics, Inc. has a one year low of $0.34 and a one year high of $3.18. The company has a market cap of $122.67 million, a PE ratio of -1.35 and a beta of 1.23. The business has a 50-day simple moving average of $0.53 and a 200-day simple moving average of $0.88.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. On average, sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.